Beam Therapeutics Inc [BEAM] stock is trading at $27.82, up 8.04%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BEAM shares have gain 7.37% over the last week, with a monthly amount glided 9.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on January 29, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight. Previously, Leerink Partners upgraded its rating to Outperform on November 06, 2024, and elevated its price target to $39. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $80 on July 23, 2024. JP Morgan upgraded its rating to a Overweight and raised its price target to $40 on January 29, 2024. BofA Securities downgraded its rating to Neutral for this stock on December 15, 2023, but kept the price target unchanged to $35. In a note dated December 08, 2023, Jefferies downgraded an Hold rating on this stock and revised its target price from $75 to $30.
Beam Therapeutics Inc [BEAM] stock has fluctuated between $20.84 and $49.50 over the past year. Currently, Wall Street analysts expect the stock to reach $50.5 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $27.82 at the most recent close of the market. An investor can expect a potential return of 81.52% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 349.64M for the trailing twelve months, which represents a drop of -17.01%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.16 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.51 points at the first support level, and at 25.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.51, and for the 2nd resistance point, it is at 29.19.
Ratios To Look Out For
For context, Beam Therapeutics Inc’s Current Ratio is 5.69. Further, the Quick Ratio stands at 5.69, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 6.59, the price to book ratio is 2.90.
Transactions by insiders
Recent insider trading involved Evans John M., CEO, that happened on Jan 30 ’25 when 30000.0 shares were sold. Officer, JOHN M EVANS completed a deal on Jan 30 ’25 to buy 30000.0 shares. Meanwhile, Chief Legal Officer Bellon Christine sold 1241.0 shares on Jan 02 ’25.
